Comparison 4. Budesonide versus mesalamine.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical remission (ITT analysis)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2 Clinical remission according to disease location	1	343	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.57, 0.91]
2.1 Distal Disease (combined proctosigmoiditis and left‐sided disease)	1	274	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.58, 0.96]
2.2 Extensive disease (extending proximal to the splenic flexure)	1	69	Risk Ratio (M‐H, Fixed, 95% CI)	0.64 [0.39, 1.05]
3 Therapeutic success (defined by Physician's Global Assessment)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Therapeutic benefit (defined by Physician's Global Assessment)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
5 Endoscopic improvement	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
6 Endoscopic remission (EI ≤ 1)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7 Histologic remission	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
8 Adverse events	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9 Adverse events related to study medication	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
10 Withdrawal due to adverse events	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
11 Drop in cortisol below normal lower limit at final visit	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
12 Remission (combined clinical and endoscopic remission)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13 Clinical improvement	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
14 Symptom resolution	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15 Serious adverse events	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
16 Potential glucocorticoid effects	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected